Research What we do and how? Teams Meet our people News What's happening Photogallery Be in the picture Our Partners Join our projects Contacts Addresses, emails, phones…
Research Research
Laboratory Instruments Instruments purchased through European Regional Development Fund. CZ.02.1.01/0.0/0.0/15_003/0000495
Publications Articles published under the Project FIT
Patents And Inventions Patents filed under Project FIT
Teams Teams
Pharmacology And Immunotherapy doc. RNDr. Jaroslav TURÁNEK, CSc.
Virology doc.RNDr. Daniel RŮŽEK, Ph.D.
Chemistry And Toxicology RNDr. Miroslav MACHALA, CSc.
Biotechnology and Immunology UPOL Prof. MUDr. Mgr. Milan RAŠKA, Ph.D.
News News
11th International Conference "Drug Delivery Systems" in Telč 11th international conference on Drug Delivery Systems: "Nanotechnology for Healthcare" was held at Jesuit college in Telč on 5th - 7th June 2018.
Photogallery Photogallery
Laboratories and VRI campus Place for our scientists
Laboratory Instruments These instruments were financed by Regional Development Fund. CZ.02.1.01/0.0/0.0/15_003/0000495
Events photos Conferences, seminars, visits ...
You are here:

Teams


There are three major groups working together under the Project FIT - Virology lead by Dr. Daniel Růžek, Pharmacology and Immunotherapy, Chemistry and Toxicology lead by Dr. Miroslav Machala, and one subgroup of Immunology lead by Dr. Milan Raška.



Main Research Focus:

  • Advanced vaccination and drug delivery systems
  • Biocompatible nanomaterials
  • Recombinant protein and DNA/RNA vaccines
  • Antiviral and anticancer chemotherapeutics
  • Advanced animal models and in vivo imaging methods
  • Nanotoxicology of viruses, nanomaterials and nanoparticles
 

Prof Miller is Professor of Organic Chemistry & Chemical Biology and is well known as a leading chemist expert in the understanding and exploitation of molecular mechanisms in biology. The overall aim of his academic research has been and continues to be the design and creation of advanced therapeutics and diagnostics that address unmet medical need in the treatment of chronic diseases (such as cancer, diabetes, pain and some infectious diseases). From 1990-2010, Prof Miller was a member of academic staff in the Chemistry Department of Imperial College London (UK) where he founded the Imperial College Genetic Therapies Centre (GTC) in 1998, and became full Professor of Organic Chemistry & Chemical Biology in 2002. From 2010-2017, Prof Miller was a Professor (visiting) at King’s College London from where he developed his career as an academic entrepreneur. Since the beginning of 2017, he joined part-time the Veterinary Research Institute (VRI) in Brno, Czech Republic, where he is Director andKey Foreign Scientist (KFS) for OPVVV Project FIT.
 
Most recently, from beginning 2020, Prof Miller was appointed Professor (part-time) at Mendel University in Brno, Czech Republic. In addition, he currently holds/has held a number of other professorial positions in leading universities around the World including Shanghai Jiaotong University (SJTU) (Shanghai, China), and Nagoya University (MeiDai) (Nagoya, Japan). Nowadays, Prof Miller divides his time between working in the Czech Republic and working in the UK, or elsewhere in the world, according to the varying demands of his research, teaching and/or commercialization activities.

Prof Miller has currently published over 250 papers, book chapters and alike, including at least 27 patents and patent applications. He is also principal writer of the first textbook of chemical biology (“Essentials of Chemical Biology”) published in August 2008 by John Wiley & Sons. The second edition of this textbook is expected to be published during 2021. In 2020, Prof Miller will cofound KP Therapeutics (Europe) with a pipeline of Precision Therapeutic Approaches (PTAs) in discovery & development for the diagnosis and treatment of chronic diseases. These PTAs all derive from the best of Prof Miller’s personal and collaborative academic research work over the past two decades, involving a research spend of at least £30 million.